CYP2D6 and Tamoxifen: Awaiting the Denouement Reply

被引：0
作者：
Rae, James M. [1 ]
机构：
[1] Univ Michigan, Ctr Comprehens Canc, Ann Arbor, MI 48109 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2011年 / 29卷 / 34期
关键词：
PHARMACOGENETICS; METABOLITE;
D O I：
10.1200/JCO.2011.39.0971
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：4590 / 4591
页数：3
相关论文
共 50 条
[31]   CYP2D6 polymorphisms influence the efficacy of adjuvant tamoxifen in Thai breast cancer patients [J].
Sirachainan, Ekaphop ;
Jaruhathai, Sureerat ;
Trachu, Narumol ;
Panvichian, Ravat ;
Sirisinha, Thitiya ;
Ativitavas, Touch ;
Ratanatharathorn, Vorachai ;
Chamnanphon, Montri ;
Sukasem, Chonlaphat .
PHARMACOGENOMICS & PERSONALIZED MEDICINE, 2012, 5 :149-153
[32]   Loss of Heterozygosity at the CYP2D6 Locus in Breast Cancer: Implications for Tamoxifen Pharmacogenetic Studies [J].
Johnson, Julie A. ;
Hamadeh, Issam S. ;
Langaee, Taimour Y. .
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2015, 107 (02)
[33]   CYP2D6 and Adjuvant Tamoxifen: Possible Differences in Outcome for Pre- and Postmenopausal Patients [J].
Margolin, S. ;
Lindh, J. D. ;
Thoren, L. ;
Xie, H. J. ;
Koukel, L. ;
Dahl, M. L. ;
Eliasson, E. .
THERAPEUTIC DRUG MONITORING, 2013, 35 (05) :706-707
[34]   Effects of CYP2D6*10 polymorphism on tamoxifen pharmacokinetics in patients with breast cancer in Asia: a meta-analysis [J].
Bai, Yu ;
Wu, Hai-wei ;
Zhang, Yan-hua .
CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2019, 83 (01) :71-79
[35]   Interrogation of CYP2D6 Structural Variant Alleles Improves the Correlation Between CYP2D6 Genotype and CYP2D6-Mediated Metabolic Activity [J].
Dalton, Rachel ;
Lee, Seung-been ;
Claw, Katrina G. ;
Prasad, Bhagwat ;
Phillips, Brian R. ;
Shen, Danny D. ;
Wong, Lai Hong ;
Fade, Mitch ;
McDonald, Matthew G. ;
Dunham, Maitreya J. ;
Fowler, Douglas M. ;
Rettie, Allan E. ;
Schuetz, Erin ;
Thornton, Timothy A. ;
Nickerson, Deborah A. ;
Gaedigk, Andrea ;
Thummel, Kenneth E. ;
Woodahl, Erica L. .
CTS-CLINICAL AND TRANSLATIONAL SCIENCE, 2020, 13 (01) :147-156
[36]   CYP2D6-inhibiting medication use and inherited CYP2D6 variation in relation to adverse breast cancer outcomes after tamoxifen therapy [J].
Sophie E. Mayer ;
Noel S. Weiss ;
Jessica Chubak ;
David R. Doody ;
Christopher S. Carlson ;
Karen W. Makar ;
Michelle A. Wurscher ;
Kathleen E. Malone .
Cancer Causes & Control, 2019, 30 :103-112
[37]   CYP2D6-inhibiting medication use and inherited CYP2D6 variation in relation to adverse breast cancer outcomes after tamoxifen therapy [J].
Mayer, Sophie E. ;
Weiss, Noel S. ;
Chubak, Jessica ;
Doody, David R. ;
Carlson, Christopher S. ;
Makar, Karen W. ;
Wurscher, Michelle A. ;
Malone, Kathleen E. .
CANCER CAUSES & CONTROL, 2019, 30 (01) :103-112
[38]   Involvement of CYP2D6 and CYP2B6 on tramadol pharmacokinetics [J].
Saiz-Rodriguez, Miriam ;
Ochoa, Dolores ;
Roman, Manuel ;
Zubiaur, Pablo ;
Koller, Dora ;
Mejia, Gina ;
Abad-Santos, Francisco .
PHARMACOGENOMICS, 2020, 21 (10) :663-675
[39]   Implementation of CYP2D6 genotyping in psychiatry [J].
Loovers, Harriet M. ;
van der Weide, Jan .
EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY, 2009, 5 (09) :1065-1077
[40]   CYP2D6 genotype predicts tamoxifen discontinuation and drug response: a secondary analysis of the KARISMA trial [J].
He, W. ;
Eriksson, M. ;
Eliasson, E. ;
Grassmann, F. ;
Backlund, M. ;
Gabrielson, M. ;
Hammarstrom, M. ;
Margolin, S. ;
Thoren, L. ;
Wengstrom, Y. ;
Borgquist, S. ;
Hall, P. ;
Czene, K. .
ANNALS OF ONCOLOGY, 2021, 32 (10) :1286-1293
12345